TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01148277
Drug: midazolam and fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
Study: NCT01148277
Drug: midazolam anf fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
Study: NCT00131118
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00820690
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 cycles AC: doxorubicin 60mg/m2
Study: NCT00820690
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 cycles AC: cyclophosphamide 600mg/m2
Study: NCT00654680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00012311
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00012311
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00012311
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04397094
Drug: Theracal LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: pulpotomy
Study: NCT03489629
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if \< 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42.
Study: NCT00012311
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00012311
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01141595
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
Study: NCT03528512
Drug: Midazolam and fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
Study: NCT04082000
Drug: BOL-DP-o-04
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOL-DP-o-04
Study: NCT04082000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04418297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT02144415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 x matching placebo capsules
Study: NCT03537014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo during three experimental sessions
Study: NCT00677365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same frequency as study drug using the same nebulizer
Study: NCT00294112
Drug: Prochymal™ adult human mesenchymal stem cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cells in plasmalyte and containing dimethylsulfoxide
Study: NCT01587001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo three times daily for 8 weeks.
Study: NCT02173795
Drug: Berodual® MA HFA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02448732
Drug: ACM-1
Normalized name: ACMELLA OLERACEA FLOWER
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
Study: NCT02157974
Drug: Byetta 5Mcg Pen Injection
Normalized name: Byetta 5mcg Pen Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
Study: NCT02538627
Drug: MM-141
Normalized name: inositol 141 MG
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MM-141
Study: NCT01486667
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
Study: NCT03476369
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Premedicated with Fentanyl (at least 25mcg by IV)
Study: NCT04102111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral tablets of matching placebo twice daily.
Study: NCT01052298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
Study: NCT00171392
Drug: Enteric-coated mycophenolate sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03958396
Drug: Remifentanil Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
Study: NCT00864331
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy given alone
Study: NCT00887198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo tablets per day taken orally.
Study: NCT00280761
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
Study: NCT01462708
Drug: [18F]MK-9470
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not \>10% of 10 mCi limit)of \[18F\]MK-9470, followed by PET imaging.
Study: NCT00091832
Drug: IV Bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
Study: NCT02258074
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01986998
Drug: Methylprednisolone 1250 mg/24h x3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
Study: NCT02258074
Drug: Placebo (for Nicotinamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
Study: NCT03325881
Drug: SHP465
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 capsule 6.25 mg orally once daily for 4 weeks
Study: NCT03325881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to SHP465 capsule orally once daily for 4 weeks
Study: NCT02794584
Drug: sufentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study: NCT01459250
Drug: AGO178C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01986998
Drug: Oral Methylprednisolone 625 mg/24h x3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
Study: NCT01147146
Drug: propofol, fentanyl, atracurium
Approvals — FDA: no, EMA: no, PMDA: no
Description: general anesthesia
Study: NCT00915343
Drug: hydrocortisone (modified release), oral tablet 20 and 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
Study: NCT00915343
Drug: Hydrocortisone, oral tablet, 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
Study: NCT03976700
Drug: Bufei Jianpi granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
Study: NCT03976700
Drug: Placebo Bufei Jianpi granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
Study: NCT00360607
Drug: Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00360607
Drug: Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited
Normalized name: Dr. Smith's Diaper Rash
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03944915
Drug: Hydroxyurea Pill
Normalized name: hydroxyurea Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
Study: NCT00967057
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally
Study: NCT00360607
Drug: Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00360607
Drug: Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00851370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-Weekly
Study: NCT02938923
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical testosterone gel 1%
Study: NCT02938923
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive skin gel
Study: NCT03400800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT00454805
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02558374
Drug: AR-13324 Ophthalmic Solution 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop once daily (QD), PM, OU
Study: NCT05206578
Drug: AGT2, AGZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, q.d.
Study: NCT05206578
Drug: AGT4, AGZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, q.d.
Study: NCT04664959
Drug: Prolia® (Denosumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
Study: NCT03110874
Drug: one-way education
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
Study: NCT03110874
Drug: two-way education
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
Study: NCT03589560
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
Study: NCT00866385
Drug: AZD8566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 6 mg oral solution dose
Study: NCT02644135
Drug: Halo Oral Spray
Normalized name: HYDROLYZED ORYZANOL 50 mg in 1 g / ALOE PERRYI LEAF 50 mg in 1 g / ARGININE 30 mg in 1 g TOPICAL CREAM [DRUGGIST HONEY HALO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sprays per use, total = 9 sprays per day
Study: NCT02644135
Drug: Halo Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sprays per use, total = 9 sprays per day
Study: NCT03964935
Drug: Minocycline HCl 1mg Oral Powder
Normalized name: minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
Study: NCT03312478
Drug: Blood draw for insulin auto-anti body tests*
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: N/A~Route of administration: N/A
Study: NCT00706277
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil 0,25mcg/kg/hour
Study: NCT00706277
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 100mcg
Study: NCT02318771
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03673215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
Study: NCT03673215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
Study: NCT03673215
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
Study: NCT00418938
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m\^2 IV (in the vein)
Study: NCT02784275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00679705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 5%, IV
Study: NCT01482845
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
Study: NCT01482845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
Study: NCT00105937
Drug: OraVescent fentanyl citrate
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04528108
Drug: Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
Study: NCT00546052
Drug: losartan potassium (+) hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan potassium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
Study: NCT02305862
Drug: Rosuvastatin 5mg
Normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug intervention
Study: NCT02305862
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug intervention
Study: NCT03156816
Drug: Placebo group (control arm)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
Study: NCT01558271
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01558271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01721655
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
Study: NCT01721655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
Study: NCT00178178
Drug: Bupivicaine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Bupivicaine 0.5 %
Study: NCT00178178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo
Study: NCT01493336
Drug: capecitabine RTD
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single oral dose
Study: NCT01411748
Drug: mikostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50000 unit/3 times a day, both for orally and by orogastric route
Study: NCT04609189
Drug: Calcium carbonate/vitamin D3
Normalized name: calcium carbonate/vitamin D3 180 mg-5,000 unit ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Calcium Carbonate/Vitamin D3
Study: NCT01823679
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00465959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01526512
Drug: metroCX
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
Study: NCT01691209
Drug: 1% Hydrocortison cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Hydrocortison cream applied to the skin
Study: NCT03536455
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT01531283
Drug: combined acyl and desacyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
Study: NCT01175785
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02116010
Drug: E. coli Phages cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
Study: NCT02116010
Drug: P. Aeruginosa, Phages cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
Study: NCT00221403
Drug: Valproate Oral Solution
Normalized name: valproate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid, BID dosing.
Study: NCT02600507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00967590
Drug: RO5036505
Approvals — FDA: no, EMA: no, PMDA: no
Description: 380mg iv infusion once weekly for 8 weeks
Study: NCT00967590
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv infusion once weekly for 8 weeks
Study: NCT00779285
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
Study: NCT04026997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02389361
Drug: Zaldiar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)